Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage Cell Signaling Technology
PhosphoSitePlus
HomeAbout PhosphoSiteUsing PhosphoSiteCuration ProcessContact
NIH-logos NIGMS Logo NIAAA Logo NCI Logo NIH Logo
Curated Information Page
PubMed Id: 17105820 
Irish JM, et al. (2007) Flt3 Y591 duplication and Bcl-2 overexpression are detected in acute myeloid leukemia cells with high levels of phosphorylated wild-type p53. Blood 109, 2589-96 17105820
This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2012,40:D261-70). To learn more about the scope of PhosphoSitePlus®, click here.
Only sites from this record are displayed on this page. Click on the protein name to open the protein page, and on the RSD number to open the site page. For the complete dataset, click the download button, on the right.
Download Sites

Y591-p - FLT3 (human)
Orthologous residues
FLT3 (human): Y591‑p, FLT3 (mouse): Y592‑p, FLT3 iso3 (mouse): Y592‑p
Associated Diseases
Diseases: Alterations: Comments:
acute myelogenous leukemia mutation of site duplication of site

S15-p - p53 (human)
Orthologous residues
p53 (human): S15‑p, p53 (mouse): S15‑p, p53 iso2 (mouse): S18‑p, p53 (rat): S15‑p, p53 (rabbit): S15‑p, p53 (monkey): S15‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Disease tissue studied:  leukemia, acute myelogenous leukemia, prostate cancer
 Relevant cell lines - cell types - tissues:  leukocyte-blood, LNCaP (prostate cell), MOLM 13 (myeloid)
 Cellular systems studied:  cell lines, primary cells
 Species studied:  human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
idarubicin increase most AML patients increased

S20-p - p53 (human)
Orthologous residues
p53 (human): S20‑p, p53 (mouse): S20‑p, p53 iso2 (mouse): S23‑p, p53 (rat): S20‑p, p53 (rabbit): S20‑p, p53 (monkey): S20‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Disease tissue studied:  leukemia, acute myelogenous leukemia, prostate cancer
 Relevant cell lines - cell types - tissues:  leukocyte-blood, LNCaP (prostate cell), MOLM 13 (myeloid)
 Cellular systems studied:  cell lines, primary cells
 Species studied:  human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
idarubicin increase most AML patients increased

S37-p - p53 (human)
Orthologous residues
p53 (human): S37‑p, p53 (mouse): S34‑p, p53 iso2 (mouse): S37‑p, p53 (rat): S39‑p, p53 (rabbit): N37‑p, p53 (monkey): S37‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Disease tissue studied:  leukemia, acute myelogenous leukemia, prostate cancer
 Relevant cell lines - cell types - tissues:  leukocyte-blood, LNCaP (prostate cell), MOLM 13 (myeloid)
 Cellular systems studied:  cell lines, primary cells
 Species studied:  human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
ionizing radiation increase
idarubicin increase most AML patients increased

S46-p - p53 (human)
Orthologous residues
p53 (human): S46‑p, p53 (mouse): L43‑p, p53 iso2 (mouse): L46‑p, p53 (rat): L48‑p, p53 (rabbit): S45‑p, p53 (monkey): S46‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Disease tissue studied:  leukemia, acute myelogenous leukemia, prostate cancer
 Relevant cell lines - cell types - tissues:  leukocyte-blood, LNCaP (prostate cell), MOLM 13 (myeloid)
 Cellular systems studied:  cell lines, primary cells
 Species studied:  human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
ionizing radiation increase
idarubicin increase most AML patients increased

S392-p - p53 (human)
Orthologous residues
p53 (human): S392‑p, p53 (mouse): S386‑p, p53 iso2 (mouse): , p53 (rat): S390‑p, p53 (rabbit): S390‑p, p53 (monkey): S392‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Disease tissue studied:  leukemia, acute myelogenous leukemia, prostate cancer
 Relevant cell lines - cell types - tissues:  leukocyte-blood, LNCaP (prostate cell), MOLM 13 (myeloid)
 Cellular systems studied:  cell lines, primary cells
 Species studied:  human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
ionizing radiation increase
idarubicin increase most AML patients increased


Home  |  Curator Login With enhanced literature mining using Linguamatics I2E I2E Logo Produced by 3rd Millennium  |  Design by Digizyme
©2003-2013 Cell Signaling Technology, Inc.